MetaCap

BridgeBio Pharma Inc. (BBIO)

NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

76.03-2.15 (-2.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BBIO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$14.81B
EPS (TTM)
-$3.03
52-week range
62.50 – 93.42
Day range
75.46 – 78.22
Volume / Avg
1.48M / 2.67M
Beta
—

52-week range

$62.50$93.42

BBIO stock today

On Nov 20, BBIO ended the session at $76.03, shedding $2.15 (2.75%), versus the S&P 500's 3.70% decline. At this level, BBIO sits in the middle of its 52-week range of $62.50 to $93.42: 18.6% below the high, set on Jul 9, 2026 and 21.6% above the low. BBIO is down 0.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 11.6%.

BridgeBio Pharma has posted a net loss over the last twelve months (EPS of -$3.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BridgeBio Pharma

Company profile

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Neil Kumar Ph.D.
Headquarters
Palo Alto, CA
Employees
1,081
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, BridgeBio Pharma generated $502.1 million in revenue, up 126.3% from fiscal 2024, its 2nd consecutive year of revenue growth. BridgeBio Pharma reported a net loss of $732.9 million, compared with a loss of $543.3 million a year earlier. Gross margin was 95.8% (down from 98.3%) and operating margin -104.2%.

BridgeBio Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$502.08M$221.90M$9.30M$77.65M$69.72M
Growth+126.26%+2285.27%-88.02%+11.38%+745.14%
Net income$-732.94M$-543.35M$-653.25M$-484.65M$-586.45M
EPS (diluted)$-3.78$-2.88$-3.95$-3.26$-3.90

Analyst forecast

Forecast

Consensus (22 analysts)

strong_buy

Avg. price target

$107.00+40.73%

  • Strong buy 5
  • Buy 14
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $80.00High $156.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.42 vs $-0.60
Surprise
+30.00%

BBIO news

All BBIO news

BridgeBio Pharma peers

Health Care sector
BBIO peer companies
CompanyPrice% ChgMarket capCompare
JAZZJazz Pharmaceuticals plc230.26-2.62%$14.78Bvs BBIO
ASNDAscendis Pharma A/S252.73-1.26%$16.58Bvs BBIO
ELANElanco Animal Health Incorporated25.74-2.09%$12.87Bvs BBIO
RDYDr. Reddy's Laboratories Ltd14.89+0.40%$12.41Bvs BBIO
BMRNBioMarin Pharmaceutical Inc.60.41-1.64%$11.70Bvs BBIO
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs BBIO
TGTXTG Therapeutics Inc.63.34-2.37%$9.57Bvs BBIO
SYRESpyre Therapeutics Inc.93.47-4.26%$8.88Bvs BBIO

Indexes, lists and sector

BridgeBio Pharma stock FAQ

What is BridgeBio Pharma's stock price today?

BBIO last traded at $76.03 as of Nov 20, 4:00 PM EST, down 2.75% on the day. Prices are delayed at least 15 minutes.

Who is BridgeBio Pharma's CEO?

Dr. Neil Kumar Ph.D. is the chief executive officer of BridgeBio Pharma Inc., which has about 1,081 employees.

What is the BBIO 52-week high?

The 52-week high for BBIO is $93.42 and the 52-week low is $62.50. The stock is currently 18.6% below its high.

Compare BBIO